KTH222

Under evaluation from Kalos Therapeutics for the treatment of Ovarian cancer

Discovery Optimisation Pre-clinical Phase 1 Phase 2

Small molecule, peptide, New Chemical Entity (NCE);

Primary indication: Ovarian Cancer;

Under evaluation from Kalos Therapeutics;

Published research: A novel, small peptide with activity against human pancreatic cancer. Michael R Kozlowski, Roni E Kozlowski (2020) Am J Cancer Res 2020;10(5):1356-1365